EcoDrugPlus

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSOMYG00000023837
Gene Symbol: HTR1B
1 Cross references
176 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSOMYG00000000882
Gene Symbol: HTR1E
1 Cross references
139 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSOMYG00000022881
Gene Symbol: HTR1E
1 Cross references
115 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSOMYG00000033352
Gene Symbol: HTR1E
1 Cross references
139 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSOMYG00000033769
Gene Symbol: HTR2A
2 Cross references
213 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSOMYG00000060656
Gene Symbol: HTR2A
1 Cross references
212 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSOMYG00000052529
Gene Symbol: HTR3A
1 Cross references
193 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSOMYG00000037923
Gene Symbol: HTR3A
1 Cross references
196 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSOMYG00000020596
Gene Symbol: HTR3B
1 Cross references
168 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSOMYG00000037914
Gene Symbol: HTR3B
1 Cross references
170 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSOMYG00000017243
Gene Symbol: HTR4
1 Cross references
193 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSOMYG00000015610
Gene Symbol: HTR5A
1 Cross references
203 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).